Clinical trial
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With…
NCT00382811 · MEI Pharma, Inc., Industry · Completed
Key facts
| NCT number | NCT00382811 |
|---|---|
| Title | OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer |
| Official title | Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least… |
| Acronym | OVATURE |
| Lead sponsor | MEI Pharma, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer |
| Intervention type | Drug |
| Interventions | phenoxodiol, carboplatin, placebo |
| Enrollment | 142 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2011 |
| First posted | Oct 2, 2006 |
| Last update posted | Jul 18, 2016 |
| Countries | Australia, Belgium, Italy, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: